PMID- 9046948
OWN - NLM
STAT- MEDLINE
DCOM- 19970519
LR  - 20071115
IS  - 0066-4219 (Print)
IS  - 0066-4219 (Linking)
VI  - 48
DP  - 1997
TI  - Use of intravenous immunoglobulin to prevent or treat infections in persons with 
      immune deficiency.
PG  - 93-102
AB  - Intravenous immunoglobulin (IVIG) concentrates were originally developed as 
      replacement therapy for individuals with primary deficiencies of the immune 
      system. However, in various well-designed, controlled clinical trials, the 
      ability of IVIG to prevent and possibly treat infections in patients with 
      secondary immune deficiencies has also been considered. In this review, we 
      briefly consider these different applications and suggest whether the data are 
      sufficient to employ IVIG in these clinical settings.
FAU - Lee, M L
AU  - Lee ML
AD  - International Quantitative Consultants, Inc., Glendale, California 91203, USA.
FAU - Gale, R P
AU  - Gale RP
FAU - Yap, P L
AU  - Yap PL
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Annu Rev Med
JT  - Annual review of medicine
JID - 2985151R
SB  - IM
MH  - Acquired Immunodeficiency Syndrome/immunology/therapy
MH  - Clinical Trials as Topic
MH  - Humans
MH  - Immunization, Passive/*methods
MH  - Immunologic Deficiency Syndromes/immunology/*therapy
MH  - Infusions, Intravenous
MH  - Opportunistic Infections/immunology/*therapy
MH  - Treatment Outcome
RF  - 112
EDAT- 1997/01/01 00:00
MHDA- 1997/01/01 00:01
CRDT- 1997/01/01 00:00
PHST- 1997/01/01 00:00 [pubmed]
PHST- 1997/01/01 00:01 [medline]
PHST- 1997/01/01 00:00 [entrez]
AID - 10.1146/annurev.med.48.1.93 [doi]
PST - ppublish
SO  - Annu Rev Med. 1997;48:93-102. doi: 10.1146/annurev.med.48.1.93.